AU2001270962B8 - Phospholipid derivatives of valproic acid and mixtures thereof - Google Patents

Phospholipid derivatives of valproic acid and mixtures thereof Download PDF

Info

Publication number
AU2001270962B8
AU2001270962B8 AU2001270962A AU2001270962A AU2001270962B8 AU 2001270962 B8 AU2001270962 B8 AU 2001270962B8 AU 2001270962 A AU2001270962 A AU 2001270962A AU 2001270962 A AU2001270962 A AU 2001270962A AU 2001270962 B8 AU2001270962 B8 AU 2001270962B8
Authority
AU
Australia
Prior art keywords
valproic acid
pharmaceutically acceptable
vpa
acceptable derivative
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001270962A
Other languages
English (en)
Other versions
AU2001270962B2 (en
AU2001270962A1 (en
Inventor
Alexander Kozak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D Pharm Ltd
Original Assignee
DPHARM Ltd
D Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DPHARM Ltd, D Pharm Ltd filed Critical DPHARM Ltd
Publication of AU2001270962A1 publication Critical patent/AU2001270962A1/en
Publication of AU2001270962B2 publication Critical patent/AU2001270962B2/en
Application granted granted Critical
Publication of AU2001270962B8 publication Critical patent/AU2001270962B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001270962A 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof Ceased AU2001270962B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/614,271 2000-07-12
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
PCT/IL2001/000629 WO2002007669A2 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Publications (3)

Publication Number Publication Date
AU2001270962A1 AU2001270962A1 (en) 2002-05-02
AU2001270962B2 AU2001270962B2 (en) 2006-03-16
AU2001270962B8 true AU2001270962B8 (en) 2006-08-10

Family

ID=24460534

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001270962A Ceased AU2001270962B8 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof
AU7096201A Pending AU7096201A (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU7096201A Pending AU7096201A (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Country Status (20)

Country Link
US (2) US6313106B1 (enExample)
EP (1) EP1315506B1 (enExample)
JP (1) JP5140224B2 (enExample)
KR (1) KR100801213B1 (enExample)
CN (1) CN100536851C (enExample)
AT (1) ATE461697T1 (enExample)
AU (2) AU2001270962B8 (enExample)
BR (1) BR0112337A (enExample)
CA (1) CA2415354C (enExample)
CY (1) CY1110113T1 (enExample)
CZ (1) CZ305745B6 (enExample)
DE (1) DE60141636D1 (enExample)
DK (1) DK1315506T3 (enExample)
ES (1) ES2343403T3 (enExample)
HU (1) HU229320B1 (enExample)
IL (1) IL153147A0 (enExample)
MX (1) MXPA03000326A (enExample)
NZ (1) NZ522788A (enExample)
PT (1) PT1315506E (enExample)
WO (1) WO2002007669A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
AU2003217791A1 (en) 2002-02-28 2003-09-16 A And D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
EP1928807A4 (en) * 2005-09-02 2011-05-04 Picobella Llc ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
AU2013257710B2 (en) * 2012-05-08 2016-10-20 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022483A2 (en) * 1993-03-31 1994-10-13 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
JP3019994B2 (ja) 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
WO1990010448A2 (en) 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (enExample) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022483A2 (en) * 1993-03-31 1994-10-13 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells

Also Published As

Publication number Publication date
WO2002007669A2 (en) 2002-01-31
IL153147A0 (en) 2003-06-24
EP1315506A2 (en) 2003-06-04
ATE461697T1 (de) 2010-04-15
WO2002007669A3 (en) 2003-01-09
CN100536851C (zh) 2009-09-09
AU7096201A (en) 2002-02-05
KR100801213B1 (ko) 2008-02-05
US20040033987A1 (en) 2004-02-19
CY1110113T1 (el) 2015-01-14
BR0112337A (pt) 2004-06-08
CA2415354C (en) 2009-09-29
EP1315506A4 (en) 2005-03-30
KR20030034099A (ko) 2003-05-01
AU2001270962B2 (en) 2006-03-16
HUP0302635A3 (en) 2007-06-28
DE60141636D1 (de) 2010-05-06
HU229320B1 (en) 2013-10-28
CN1774252A (zh) 2006-05-17
JP5140224B2 (ja) 2013-02-06
CZ305745B6 (cs) 2016-03-02
HUP0302635A2 (hu) 2003-11-28
CZ200386A3 (cs) 2003-06-18
JP2004509854A (ja) 2004-04-02
CA2415354A1 (en) 2002-01-31
DK1315506T3 (da) 2010-05-31
EP1315506B1 (en) 2010-03-24
US6313106B1 (en) 2001-11-06
NZ522788A (en) 2005-04-29
PT1315506E (pt) 2010-05-17
ES2343403T3 (es) 2010-07-30
MXPA03000326A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
AU2001270962B2 (en) Phospholipid derivatives of valproic acid and mixtures thereof
AU2001270962A1 (en) Phospholipid derivatives of valproic acid and mixtures thereof
US6153653A (en) Choline compositions and uses thereof
US6682758B1 (en) Water-insoluble drug delivery system
Zhao et al. Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with “lock-in” function
JP7610208B2 (ja) 足場部分から調製した脂質結合体
US5977174A (en) Cholinergic compositions and uses thereof
US5284867A (en) NMDA-blocking pharmaceutical compositions
US6251946B1 (en) Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
EP3388417A1 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
US6252060B1 (en) Antiviral liponucleosides: treatment of hepatitis B
EP1140017B1 (en) Water-insoluble drug delivery system
CA3055464A1 (en) Acefapc for the treatment of acetylcholine-dependent diseases
KR20220140563A (ko) 카나비노이드 설페이트 에스테르, 이들의 염 및 이의 사용
US20020042445A1 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7173018B2 (en) Phospholipid derivatives of non-steroidal anti-inflammatory drugs
IL153147A (en) Pharmaceutical compositions comprising phospholipid conjugates of valproic acid or derivatives thereof
IL92238A (en) ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
US20250127804A1 (en) Ribose linkers and conjugates thereof
KR100263085B1 (ko) 신규의 알카로이드 유도체, 이의 용도 및 이를 함유한 제약적 조성물
Reddy et al. Lipid-based anticancer prodrugs
KR840001917B1 (ko) 글리세릴 1,2-비스-(디-n-프로필아세테이트)와 글리세릴 1,3-비스-(디-n-프로필아세테이트) 혼합물의 제조방법
WO2016116603A1 (de) Neuartige phenylphosphate und deren verwendung als arzneimittel

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired